Sergio Raposeiras-Roubín

3 weeks ago | healio.com | Katie Kalvaitis |Richard Smith |Sergio Raposeiras-Roubín |Deepak L. Bhatt

• Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent TAVR. • Genital infections and hypotension were more common in the dapagliflozin group. CHICAGO — The first trial to evaluate use of an SGLT2 inhibitor in people undergoing transcatheter aortic valve replacement showed benefit with dapagliflozin compared with standard care alone, including in older patients.